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Abstract: Predicting the timing of a castrate resistant prostate cancer is critical to lowering
medical costs and improving the quality of life of advanced prostate cancer patients. We formulate,
compare and analyze two mathematical models that aim to forecast future levels of prostate-specific
antigen (PSA). We accomplish these tasks by employing clinical data of locally advanced prostate cancer
patients undergoing androgen deprivation therapy (ADT). While these models are simplifications of
a previously published model, they fit data with similar accuracy and improve forecasting results.
Both models describe the progression of androgen resistance. Although Model 1 is simpler than
the more realistic Model 2, it can fit clinical data to a greater precision. However, we found that
Model 2 can forecast future PSA levels more accurately. These findings suggest that including more
realistic mechanisms of androgen dynamics in a two population model may help androgen resistance
timing prediction.
Keywords: mathematical modeling; prostate cancer; androgen deprivation therapy; data fitting
1. Introduction
Ever since the discovery of androgen dependency of prostate cells, androgen deprivation therapy
(ADT) has played a vital role in the treatment of metastatic and locally advanced prostate cancer [1–3].
However, controversy remains regarding its best application. Although this treatment will regress
tumors in over 90% of patients [4], after prolonged androgen depletion, patients will eventually
develop castration-resistant prostate cancer (CRPC) [5]. The development of CRPC can take from
a few months to more than ten years [3,6], after which there is a very limited number of effective
treatments and patients suffer high mortality [7]. ADT is expensive and its side effects include sexual
dysfunction, hot flashes, and fatigue [8]. Based on some preclinical studies, intermittent androgen
suppression (IAS) is suggested as a sensible alternative to ADT [9]. During off-treatment periods,
patients enjoy a “vacation” from the severe side effects of ADT [8], and studies have suggested that
IAS may not negatively affect the time to resistance progression or survival in comparison to ADT [10].
Consequently, IAS is selected by some patients to improve the quality of life and also hopefully to
delay the progression to CRPC [4].
Many mathematical models have studied the dynamics of prostate cancer during ADT or
IAS [11–18]. A detailed review of some of these models are presented in the recent book of
Kuang et al. [19]. Ideta et al. are pioneers of mathematically modeling and analyzing the dynamics
of IAS [12]. They formulated a system of ordinary differential equations to study the mechanics of
ADT and IAS. They considered castrate-resistant (CR) and castrate-sensitive (CS) cell populations as
well as androgen levels. Their model included mutations from CS to CR cells, and their focus was on
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comparing continuous and intermittent therapy and the development of resistance. Hirata et al. [14]
introduced a piece-wise linear model of three cancer cell populations. Their model included CS cells,
CR cells that may mutate into CS cells, and CR cells that will not mutate. Several investigators using
Hirata et al.’s model [14] have studied estimation of parameters [20,21], optimal switching times and
control in IAS [20,22,23], and forecasting CRPC progression [24,25].
Built on the works of Ideta et al. [12] and Jackson [26], Portz, Kuang, and Nagy (PKN) [13] developed
a novel mathematical model to study the dynamics of IAS by using the cell quota model [27] from
mathematical ecology, which relates growth rate to an intracellular nutrient, to modeling the growth
of both the CS and CR cell populations. The cell quota in [13] is defined as the intracellular androgen
concentrations for each cell population. This model is carefully fitted with clinical prostate-specific
antigen (PSA) data, where androgen data was used to model the cell quota and other growth
parameters. Everett et al. [28] compared the models of Hirata et al. [14] and PKN [13] regarding
their accuracy of fitting clinical data and predicting future PSA levels. They concluded that while
a biologically-based model is important to reveal the underlying processes and my present more robust
and better predictions, a simpler model such as that of Hirata et al. might also be practical for fitting
clinical data and predicting future PSA outcomes of individual patients.
In this paper, we present a simplified model to the final model in PKN [13]. Several key terms in
our model will be mechanistically formulated. This model is concise and amenable to systematical
mathematical analysis of its dynamics. For simplicity, we shall use serum androgen concentration to
approximate intracellular androgen. This is reasonable since androgen passively and quickly diffuses
through the prostate membrane via concentration gradient [29]. This approach is practical for a typical
clinical setting, where the data collected can be applied directly to the model. Most importantly,
our model can fit PSA and androgen values simultaneously, which enables us to be more accurate in
making future PSA value predictions.
2. Clinical Trial Data
We use data from Bruchovsky et al. [9] in our analysis and model calibration. This clinical trial
admitted patients who demonstrated a rising serum PSA level after they received radiotherapy and
had no evidence of metastasis [9]. The treatment in each cycle consisted of administering cyproterone
acetate for four weeks, followed by a combination of leuprolide acetate and cyproterone acetate,
for an average of 36 weeks. If serum PSA is less than 4 µgL by the end of this period, the androgen
suppression therapy is stopped. If a patient’s serum PSA stays above the threshold, the patient will
be taken off of the study. After treatment is interrupted, PSA and androgen are monitored every
four weeks. The therapy is restarted when patient’s serum PSA increases to ≥10 µg/L [9]. The data set
is available at [30]. Figure 1 shows a typical patient that undergoes IAS.
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Figure 1. Sample data for prostate-specific antigen (PSA) and androgen data for a patient in a clinical trial.
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3. Formulation of Mathematical Models
We develop two plausible mathematical models to study the temporal dynamics of prostate cancer
progression to CRPR. In Model 1, we do not distinguish CS from CR cells. In this model, tumor cells’
death rate is assumed to be a monotonically decreasing exponential function to implicitly account for
the resistance development in cancer cells. Then, we propose a two cell population model where we
separate CS from CR cells explicitly. To be more biologically relevant and consistent with the PKN
model formulation, we assume in Model 2 that the development of cancer cell resistance to IAS is
a decreasing function of androgen levels.
In both models, the cell growth rate is determined by the androgen cell quota. Specifically, as in
the PKN model [13], we model the growth rate by a two parameter function of androgen cell quota,
G (Q ) = µ (1 − q
Q
), (1)
where Q is the androgen cell quota. Equation (1) is known as Droop equation or a Droop growth rate
model [19]. It assumes that Q is the concentration of the most limiting resource or nutrient, and q is the
minimum level of Q required to prevent cell death [27].
To be biologically relevant, for both models, we assume that the initial values for all variables
are positive. This shall ensure that all components of their solutions are positive. Accordingly,
we are only interested in studying the stabilities of nonnegative steady states and their biological and
clinical implications.
3.1. Model 1: Single Population Model
In the following model, tumor cell volume is denoted by x (mm3), and we assume that the
total volume is a combination of CS and CR cells. Intracellular androgen cell levels are denoted by
Q (nM), and PSA levels by P ( µgL ). Droop’s equations govern the growth rate of cancer cells [27],
where µ represents the maximum cell growth rate and q the minimum concentration of androgen to
sustain the tumor. Similar to [28], we assume an androgen-dependent death rate, where R denotes
the half saturation level. However, we also assume a time dependent maximum baseline death rate ν ,
which decreases exponentially at rate d to reflect the cell castration-resistance development due to the
decreasing death rate. We also include a density-independent death rate δ that constrains the total
volume of cancer cells to be within realistic ranges [31]:
dx
dt
= µ (1 − q
Q
)x︸      ︷︷      ︸
growth
− (ν R
Q + R
+ δx )x︸              ︷︷              ︸
death
, (2)
dν
dt
= −dν , (3)
dQ
dt
= γ︸︷︷︸
production
(Qm −Q )︸     ︷︷     ︸
diffusion
− µ (Q − q)︸    ︷︷    ︸
uptake
, (4)
dP
dt
= bQ︸︷︷︸
baseline
+ σxQ︸︷︷︸
tumor production
− ϵP︸︷︷︸
clearance
, (5)
γ = γ1u (t ) +γ2, u (t ) =
{
1, on treatment,
0, off treatment.
(6)
In this model, androgen is assumed to be the most limiting nutrient. We assume that the androgen
concentration in cancer cells is approximately the same as the androgen concentration in serum [29].
Parameter γ1 denotes the constant production of androgen by the testes, and γ2 denotes the production
of androgen by the adrenal gland and kidneys. As over 95% of androgen is produced in the testes,
we have that γ1 >> γ2. Parameter u (t ) is a switch between on and off treatment cycles. Luteinizing
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hormone releasing hormone agonists only stop testes production of androgen during treatment.
During treatment, γ2 will be the only production of androgen. Qm > q denotes the maximum androgen
level in serum. The androgen uptake by prostate cells is assumed to be proportional to the difference
of the maximum possible and the current androgen levels in serum. Androgen in cells is depleted for
growth at a rate of µ (Q − q). PSA is produced by both the regular cells in the prostate at the rate bQ
and by the cancer cells at the rate σxQ . Notice that we have assumed that cell production of PSA is
assumed to be dependent on levels of androgen. Finally, PSA is cleared from serum at rate ϵ .
3.2. Model 2: Two Population Model
Now, we present a two cell population model. In this model, we explicitly differentiate between
CS and CR cells. x1 (mm3) and x2 (mm3) denote the CS and CR cell populations, respectively.
The proliferation of each cancer cell population is denoted by
Gi (Q ) = µ (1 − qi
Q
), i = 1, 2,
for x1 and x2 respectively. Since CR cell populations proliferate at lower levels of androgen, we assume
that q2 < q1. Death rates are denoted by:
Di (Q ) = di
Ri
Q + Ri
, i = 1, 2,
for their respective cell populations. We shall assume that d1 > d2, as CR cells are less susceptible to
apoptosis by androgen deprivation than CS cells. Parameters δi , i = 1, 2 denote the density dependent
death rates, and we use these parameters to keep the maximum tumor volume in biological ranges.
Mutation between cell populations is assumed to take the form of a Hill equation of coefficient 1,
given by:
λ(Q ) = c
K
Q +K︸             ︷︷             ︸
CS to CR
.
The CS to CR rate, λ(Q ), is a decreasing function of the androgen levels. We assume that when
cells are experiencing androgen depletion, they have higher selective pressure to develop resistance.
Likewise, in an androgen rich environment, CS cells are more likely to stay sensitive. IAS started under
this assumption, with the intention to delay resistance [10]. c is the maximum rate of mutation between
cells and K is the cell concentration for achieving half of the maximum rate of mutation. In this model,
dis are held constant and are not time dependent, as the mechanism of the development of resistance
is due to mutations from x1 to x2 via λ(Q ) and not by a decreasing androgen dependent death rate.
The increase of intracellular androgen levels by diffusion from the serum level is modeled by
γ (Qm −Q ). For simplicity, and in contrast to the PKN model [13] and the model in Morken et al. [32],
we assume the same PSA production rate σ for both cell populations:
dx1
dt
= µ (1 − q1
Q
)x1︸        ︷︷        ︸
growth
− (D1 (Q ) + δ1x1)x1︸                ︷︷                ︸
death
− λ(Q )x1︸  ︷︷  ︸
CS to CR
, (7)
dx2
dt
= µ (1 − q2
Q
)x2︸        ︷︷        ︸
growth
− (D2 (Q ) + δ2x2)x2︸                ︷︷                ︸
death
+ λ(Q )x1︸  ︷︷  ︸
CS to CR
, (8)
dQ
dt
= γ︸︷︷︸
production
(Qm −Q )︸     ︷︷     ︸
diffusion
− µ (Q − q1)x1 + µ (Q − q2)x2
x1 + x2︸                             ︷︷                             ︸
uptake
, (9)
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dP
dt
= bQ︸︷︷︸
baseline
+ σ (Qx1 +Qx2)︸           ︷︷           ︸
tumor production
− ϵP .︸︷︷︸
clearence
. (10)
In a biologically realistic situation, one expects that Qm > max{q1,q2}.
3.3. Derivation of dQ/dt
Now, we provide a conservation law based derivation for the cell quota Q Equations (4) and (9).
Specifically, we derive Equation (4) in detail and leave to the readers the straightforward task of its
extension to (9). Our formulation comes from the conservation of androgen as it moves in and out of
the tumor. Let Qx be the total androgen inside tumor x (mm3). We assume that Q (nM )is uniformly
distributed in x , and
Qx = Q (t )x (t ) nmol.
The inflow of androgen to the tumor comes from the serum which can be approximated by
γ (Qm −Q (t ))x (t ).
The outflow of androgen from the tumor is due to death, which is
(ν
R
Q + R
+ δx (t ))Q (t )x (t ).
Then, the rate of change of androgen inside the tumor is:
(Q (t )x (t ))′ = γ (Qm −Q (t ))x (t ) − (ν R
Q (t ) + R
+ δx (t ))Q (t )x (t ).
However,
(Q (t )x (t ))′ = Q ′(t )x (t ) +Q (t )x ′(t )
= Q ′(t )x (t ) + µ (Q (t ) − q)x (t ) − (ν R
Q (t ) + R
+ δx (t ))Q (t )x (t ),
which implies that
Q ′(t ) = γ (Qm −Q (t )) − µ (Q (t ) − q).
A similar approach can be applied to derive Q ′(t ) for Model 2.
3.4. Portz, Kuang, and Nagy (PKN) Model
In this section, we briefly review the PKN model. For a more detailed explanation of this
model, the reader is referred to [13]. The PKN model assumes constant death rates for cancer cells
(d1,d2). CS and CR cells have androgen cell quota Q1,Q2 respectively. A denotes the serum androgen
concentration, which is interpolated and used in the model:
dx1
dt
= µm (1 − q1
Q1
)x1︸           ︷︷           ︸
growth
− d1x1︸︷︷︸
death
− λ1 (Q1)x1︸    ︷︷    ︸
CS to CR
+ λ2 (Q2)x2︸    ︷︷    ︸
CR to CS
, (11)
dx2
dt
= µm (1 − q2
Q2
)x2︸           ︷︷           ︸
growth
− d2x2︸︷︷︸
death
− λ2 (Q2)x2︸    ︷︷    ︸
CR to CS
+ λ1 (Q1)x1︸    ︷︷    ︸
CS to CR
, (12)
dQ1
dt
= vm
qm −Q1
qm − q1
A
A+vh︸                  ︷︷                  ︸
Androgen influx to CS cells
− µ (Q1 − q1)︸      ︷︷      ︸
uptake
− bQ1︸︷︷︸
degradation
, (13)
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dQ2
dt
= vm
qm −Q2
qm − q2
A
A+vh︸                  ︷︷                  ︸
Androgen influx to CR cells
− µ (Q2 − q2)︸      ︷︷      ︸
uptake
− bQ2︸︷︷︸
degradation
, (14)
dP
dt
= σ0 (x1 + x2)︸       ︷︷       ︸
baseline production
+ σ1x1
Qm1
Qm1 + ρ
m
1︸            ︷︷            ︸
tumor production
+ σ2x2
Qm2
Qm2 + ρ
m
2︸            ︷︷            ︸
tumor production
− δP .︸︷︷︸
clearence
. (15)
4. Model Dynamics
Now, we study the mathematical properties and dynamics of our two models. For Model 1,
we shall state the results without providing proofs as they are routine. The detailed mathematical
analysis for Model 2 will be presented. Proposition 1 summarizes the mathematical dynamics of
Model 1. Since P is decoupled from the system, we shall refer only to the dynamics of Equations (2)–(4).
This proposition reveals that there is no cure for cancer. Since ADT is non-curative, this property is
biologically reasonable.
Proposition 1. Solutions of the system Equations (2)–(4) are positive and bounded. The system Equations (2)–(4)
has a cancer free steady state E0 = (0, 0,
γQm+µq
µ+γ ) that is unstable, and a steady state E1 = (
µγ
δ
Qm−q
γQm+µq
, 0, γQm+µqµ+γ )
that is globally stable.
Next, we do a thorough mathematical analysis of Model 2. First, we study boundedness and
positivity of the system. Followed by the number and existence of steady states. Finally, we analyze
the local stability of the steady states. Observe that P is also decoupled from Equations (2)–(4) and we
do not include it in the analysis.
Proposition 2. Assume q2 ≤ q1 < Qm and δ1 ≥ δ2. Then, solutions of Equations (7)–(9) with initial conditions
x1 (0) > 0, x2 (0) > 0, and q2 ≤ Q (0) ≤ Qm stay in the region {(x1,x2,Q ) : x1 ≥ 0,x2 ≥ 0,x1 + x2 ≤
G2 (Qm )−Dm (q2 )
δ2
,q2 ≤ Q ≤ Qm }, where Dm = min{D1 (q2),D2 (q2)}.
Proof. We note that in Equation (7), x1 appears in every term ensuring its positivity. Since x2 appears
in the first two terms of (8) and x1 appears in the last term, the positivity of x2 is also guaranteed.
In addition, q2 ≤ q1 < Qm , and
Q ′ = γ (Qm −Q ) − µ (Q −q1)x1 + µ (Q −q2)x2
x1 + x2
.
We see that Q ′(q2) > 0 and Q ′(Qm ) < 0. It is thus easy to see that q2 ≤ Q (t ) ≤ Qm for t > 0 with
initial conditions q2 ≤ Q (0) ≤ Qm .
For boundedness of x1 and x2, we let N = x1 + x2. Since we have that δ1 ≥ δ2, and the growth rate
Gi (Q ), i = 1, 2 are increasing functions of Q , we have
N ′ ≤ (G2 (Q ) −Dm )N − δ2N 2, (16)
≤ (G2 (Qm ) −Dm )N − δ2N 2, (17)
which implies that lim sup
t→∞
N (t ) ≤ G2 (Qm ) −Dm
δ2
. 
Now, we study the steady states of Model 2. We seek to understand the conditions under which
one population will overtake the other, and the circumstances under which they may coexist.
Proposition 3. Assume q2 ≤ q1 < Qm and δ1 ≥ δ2. The system Equations (7)–(9) have a CR cell only
steady state E1 = (0,
G2 (Q1 )−D2 (Q1 )
δ2
,Q1), and a coexistence steady state E2 = (
G1 (Q∗ )−D1 (Q∗ )−λ1 (Q∗ )
δ1
,x∗2,Q
∗),
where Q1 = γQm+µq2γ+µ and Q
∗ > Q1.
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Proof. Let E = (x∗1,x
∗
2,Q
∗) be a steady state of the system Equations (7)–(9). We have two mutually
exclusive cases: x∗1 = 0 and x
∗
1 > 0.
If x∗1 = 0, then we have two possibilities: (i) x
∗
2 = 0 or (ii) x
∗
2 > 0. In the case of (i), we see that
E = E0. In the case of (ii), we see that E = E1.
If x∗1 > 0, we see that x
∗
2 > 0 from the equation of dx2/dt . In this case, E = E2. In addition, we have
the following:
0 = γ (Qm −Q∗) −
µ (Q∗ −q1)x∗1 + µ (Q∗ −q2)x∗2
x∗1 + x
∗
2
(18)
≥ γ (Qm −Q∗) − µ (Q∗ −q2)
Q∗ ≥ γQm + µq2
γ + µ
= Q1.
This proves the proposition. 
Proposition 3 demonstrates that if the CS cell population survives, then the CR must also survive.
Biologically, this makes sense, as the CR will always receive new mutated CR cells as ADT continues.
Next, we study the extinction of cancer cell populations and stability conditions for each of these
steady states when feasible. Observe that we can not linearize at the steady state E0 since the last term
of dQ/dt is not differentiable at E0. This prevents us from carrying out a routine local stability analysis
of E0.
Proposition 4 below simply confirms the intuition that if both cancer cell populations growth
rates are too low, they will die out eventually. For ease of computations in the following propositions,
we shall define S1 (Q ) = G1 (Q ) −D1 (Q ) − λ(Q ) and S2 (Q ) = G2 (Q ) −D2 (Q ) .
Proposition 4. Assume that S1 (Qm ) < 0, then CS population will die out. If, in addition, S2 (Qm ) < 0, then both
cancer populations will die out.
Proof. Observe that both S1 (Q ) and S2 (Q ) are strictly increasing with respect to positive values
of Q . Since,
x ′1 (t )
x1 (t )
= G1 (Q ) −D1 (Q ) − λ(Q ) − δ2x1,
and S1 (Qm ) < 0, we know that G1 (Q ) −D1 (Q ) − λ(Q ) ≤ S1 (Qm ) < 0 for any Q . Let m = −S1 (Qm ), and,
since x1 (t ) > 0, we have that
x ′1 (t )
x1 (t )
≤ −m
x1 (t ) ≤ ce−mt .
Therefore limt→∞ x1 (t ) = 0. Applying a similar but slightly more delicate comparison argument to
x2 (t ) with limt→∞ x1 (t ) = 0 yields limt→∞ x2 (t ) = 0. This completes the proof of this proposition. 
The following proposition provides a simple set of conditions that yields the biologically realistic
final outcome when sensitive cells are overtaken by resistant cells.
Proposition 5. The CR only steady state E1 is locally asymptotically stable when S1 (Q1) < 0 and S2 (Q1) > 0.
Proof. The Jacobian matrix evaluated at E1 is given by:
J (E1) =
*...,
S1 (Q
1) 0 0
λ(Q1) −S2 (Q1) ( µq2Q2 + d2(R2+Q )2 )
G2 (Q1 )−D2 (Q1 )
δ2
µδ2 (q1−q2 )
G2 (Q1 )−D2 (Q1 ) 0 −γ − µ
+///- .
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The eigenvalues are the diagonal elements. We see that when G1 (Q1) −D1 (Q1) − λ1 (Q1) < 0 and
G2 (Q
1) −D2 (Q1) > 0, all diagonal elements are negative. Hence, E1 is locally asymptotically stable. 
If both CS and CI cells can proliferate under treatment, then the coexistence equilibrium may be
stable. Figure 2 displays the regions where this could happen. If CS cells have a high growth rate µ,
they may survive under relatively low levels of androgen. Alternatively, if these cells have a very low
death rate d1, they may persist as well.
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Figure 2. Bifurcation diagram displaying x1 cell population vs. parameters µ and γ (left) and γ and d1
(right). This figure depicts the regions in which x1 can go extinct. This happens when androgen levels
γ are very low, or cancer cells’ proliferation rate µ is very low, or cancer cells’ death rate d1 is very high.
5. Parameter Estimation
In order to perform realistic model simulations, we need to obtain reasonable parameter values
and their ranges. We start by estimating the realistic ranges for each of them. Parameters µ, d1,d2 are
taken from [33], where they assess the growth and death rates of prostate cells under different
concentrations of androgen. In [12], it was shown that, under continuous treatment, the fastest
resistance rate is c ≈ 0.0001. The approximate levels at which sensitive and resistant cells proliferate
was studied in [34], from which we approximated q,q1, and q2.
In patients with no prostate cancer, PSA levels are usually less than 5 µgL , accounting for benign
tumor hyperplasia [8]. This implies that when tumor volume is near zero, the steady state of PSA
given by: bQϵ shall be approximately 5
µg
L . Prostate tumor volumes are normally bounded by 80 mm
in length and, on average, they are about 13.4 mm [31]. Since all of our patients have advanced
prostate cancer, we assumed a maximum length of 40 mm, and we compute the corresponding tumor
volume assuming that tumors are spherical. Under complete androgen independence, tumor volume
should not exceed 700 (mm3). Thus, µδ ≈ µδ2 +
µ
δ2
≈ 700 (mm3). Parameter Qm is patient specific and
is taken from the maximum androgen serum concentration of each patient during the first 1.5 cycles
of treatment. Parameter γ1 is held constant among every patient and γ2 has a range of 0–0.01 nmolLday .
The half-saturation variables K ,R,R1, and R2 are estimated from [28]. Table 1 shows definitions, ranges,
units, and sources for each of the parameters in our models.
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Table 1. Parameter definitions, units, and ranges.
Parameters Definition Range Units Source
µ Maximum proliferation rate 0.001–0.09 day−1 [33]
q Minimum cell quota 0.1–0.5 nM [34]
q1 Minimum CS cell quota 0.1–0.5 nM [34]
q2 Minimum CR cell quota 0.1–0.3 nM [34]
b Prostate baseline PSA 0.1–2.5 10−3 µg/L/nM/day [9]
σ Tumor PSA production rate 0.001–0.9 µg/L/nM/mm3/day [28]
ϵ PSA clearance rate 0.001–0.01 day−1 [28]
d Maximum cell death rate 0.0001–0.09 day−1 [33]
d1 Maximum CS cell death rate 0.001–0.09 day−1 [33]
d2 Maximum CR cell death rate 0.0001–0.001 day−1 [33]
δ1 Density death rate 0.1–9 × 10−5 1/day/mm3 [31]
δ2 Density death rate 0.01–4.5 × 10−4 1/day/mm3 [31]
R Cell death rate half-saturation level 0–3 nM [28]
R1 CS cell death rate half-saturation level 0–3 nM [28]
R2 CR cell death rate half-saturation level 0–3 nM [28]
c1 Maximum CS to CR rate 10−5–10−4 day−1 [12]
K CS to CR half-saturation level 0–1 nM [28]
γ1 Testes androgen production 20 day−1 ad hoc
γ2 Secondary androgen production 0.001–0.01 day−1 ad hoc
Qm Maximum androgen 15–30 nM [9]
ν death rate decay rate 0.01 unitless ad hoc
5.1. Sensitivity Analysis
Sensitivity analysis can be used to show which parameters play a bigger role in a model.
The normalized sensitivity, Sp , for parameter p and state variable x is given by:
Sp =
∂x
∂p
p
x
.
Figure 3 shows the sensitivities of every parameter and state variable for Model 1. We observe
that, with the exception of d, no parameter has a much larger sensitivity than the rest. d is the only
parameter that can dramatically affect cancer cell death rate, and we see a spike in the sensitivity
figures. Cancer cell growth rate µ has the greatest effect on androgen and cancer cells, whereas σ and ϵ
play the greatest roles in PSA production. Figure 4 shows the sensitivity of each parameter in Model 2.
We see similarities with Model 1 in that µ affects the production androgen and CR cells the most.
In addition, PSA production is affected by the same parameters as in Model 1. Notice that CS cells are
affected by d1 the most since they are the most susceptible to changes in the androgen concentration.
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6. Comparison of Models
We use data from the Vancouver Prostate Center (Vancouver, BC, Canada) to validate and compare
the accuracy of each model. From the 109 patients registered, 103 were eligible for interruption of
treatment, with a PSA response rate of 95% [9]. Using the criteria of having at least 20 data points for
both androgen and PSA in the initial 1.5 cycles, we select 62 from those 109 patients. The individual
PSA and androgen mean square error (MSE) are provided in Table 2 from these 62 selected patients.
Notice that the PKN model did not include an androgen equation, and thus we cannot compare the
fittings of androgen with the PKN model.
For the PKN model, we interpolated androgen serum data using a cubic spline interpolation
between every androgen data point. This created a function in terms of time that was utilized as A in
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(13) and (14). We implemented the method used by Portz et al. [13] for generating future androgen
levels by generating a rectangular function based on the average off and on-treatment serum androgen
values. Parameter ranges were taken from PKN [13] and Everett et al. [28], and the reader is referred to
these papers for more details on forecasting serum PSA levels and parameter values of the PKN model.
For every patient selected, we fitted 1.5 cycles of treatment and performed parameter estimation. Then,
to measure the forecasting ability of every model, we ran the models for one more cycle of data using
the parameters estimated from the initial 1.5 cycles.
Table 2. Comparison of Mean Squared Error (MSE) for Androgen and prostate-specific antigen (PSA)
for the first 1.5 cycles.
Model
PSA Androgen
Min Mean Max Min Mean Max
PKN Model 0.5119 9.4463 93.1587 N/A N/A N/A
Model 1 0.9735 8.6763 71.8471 5.0351 100.1071 710.2604
Model 2 0.2461 10.3993 137.4345 5.1283 101.4763 710.4412
To compare models, we conduct simulations with MATLAB’s (MATLAB 9.1, The MathWorks,
Inc., Natick, MA, USA) built in function fmincon, which uses the Interior Point Algorithm, to find the
optimum parameters for each patient. The algorithm searches for a minimum value in a range
of pre-specified parameter ranges, which we estimated from various literature sources. We use
this algorithm to minimize the MSE for PSA and androgen data. The MSE is calculated with the
following equations:
Perror =
∑N
i=1 (Pi − Pˆi )2
N
,
Qerror =
∑N
i=1 (Qi − Qˆi )2
N
,
where N represents the total number of data points, Pi represents the PSA data value, and Pˆi the
value from the model. Likewise, Qi represents the androgen data value, and Qˆi the value from the
model. We then use an equally weighted combination of both errors
error = Perror +Qerror ,
as our objective function, which is then minimized with fmincon.
Figure 5 shows PSA fitting and forecasting simulations for patients 1, 15, 17, and 63. We selected
these patients to display the typical behavior shown in all 62 patients. Patient 1 shows that Models 1, 2,
and PKN fit data with about the same accuracy. However, PKN overshoots in forecasting and Model 2
outperforms Model 1 in forecasting. Patient 17 shows that PKN underestimates future PSA levels,
but Models 1 and 2 both perform well. Patients 15 and 63 provide the cases where PKN does a better
forecast while Models 1 and 2 still do better. The rest of the patients can be classified similarly.
Table 2 documents the error of fitting 1.5 cycles of treatment and Table 3 displays the errors in
forecasting one more cycle of treatment. On average, PKN and Model 1 perform prediction at the same
level of accuracy. However, Model 2 performs prediction on average about three times better than the
PKN model and Model 1.
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Figure 5. Simulations of fittings for every model for 1.5 cycles of treatment (left of gray line),
and one cycle of forecast (right of gray line). For these four patients, we can see that models fit
data at comparable accuracy but Model 2 perform much better in PSA forecasting.
Table 3. Comparison of forecast Mean Square Error for PSA.
Model Min Mean Max
PKN Model 12.234 162.5494 1868.6394
Model 1 11.3935 141.9280 1663.0218
Model 2 2.2727 56.3478 278.4050
7. Conclusions
The main goal of this research is to produce a basic model capable of describing prostate cancer
cell growth subject to IAS. Such a model may be amendable to detailed and systematical mathematical
and computational study aimed at revealing the near term and intermediate term growth dynamics,
including cancer cells treatment resistance development. Ultimately, such models may be helpful in
establishing user-friendly treatment tools for both patients and physicians. To this end, we presented
two models that can accurately fit clinical PSA and androgen data simultaneously. Existing models
can only fit the PSA data. While these models are simplifications of PKN, they are just as accurate
in data fitting and even better at forecasting future PSA levels. Model 1 had the lowest mean MSE
for data fitting of all the models, followed by PKN and Model 2—not surprisingly, due to its more
biologically realistic model assumptions, Model 2 had the lowest forecast MSE, with PKN doing the
worst. The unreliability of PKN’s forecasts stems from its dependence on androgen data and hence
lacks the ability to predict androgen dynamics. Androgen cell quota values, which are not directly
measurable from data, represent a significant source of uncertainty for the PKN model. Figure 6,
shows how the new models can fit clinical androgen data and reduce uncertainty. For Models 1 and 2,
Q is directly computable from clinical data.
Predicting the timing of resistance is a highly desirable objective of this modeling work. Mathematical
models alone can not make practical predictions. However, we can use these models and apply
statistical methods to produce reliable forecasts with confidence intervals [35,36]. In Pell et al. [35] and
Chowell et al. [36], the authors have used these methods successfully in an epidemiological setting
to make predictions. In a future paper, the authors plan to use the models presented in this paper
to produce predictions using such statistical methods. Therefore, the main biological contribution
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of this work is the development of a clear and basic androgen cell-quota based model to aid our
understanding of the resistance development dynamics of prostate cancer cells.
The dynamics of Model 1 is characterized by globally stable steady states. The mathematical
analysis of Model 2 is only partially tractable. In fact, the stability and global stability of the cancer
cell coexistence steady state remain unsettled. However, with our bifurcation analysis, we observe
that under ADT or IAS, x2 cells may drive x1 cells to extinction. In Figure 2, we see that with lower
and realistic levels of androgen production when the patient is under ADT, x1 cells will eventually
become extinct even at a higher level of proliferation compared to x2 cells. Thus, we concluded that,
under continuous treatment, almost all patients will eventually become androgen resistant. However,
it is still not clear if IAS delays the speed at which this occurs. With the models presented in this work,
we have moved closer to the ultimate goal of modeling the androgen resistance of prostate cancer.
Our work is limited by the small number of patients considered. We selected 62 patients that had
at least 20 data points in the first 1.5 cycles of treatment. Using a larger time interval and more patients
to calibrate models might reveal more subtle differences in the models’ ability to fit data. Additionally,
tumor volume data will allow us to validate the model more naturally. Figures 7 and 8 show the cancer
populations for Models 1 and 2 in resistant and non-resistant patients. Tumor volume data will allow
us to verify the results in these figures even if only a few data points are available.
In addition, identifiability analysis to determine if our parameter values can be represented
uniquely by clinical data is essential if these models are to be used in a clinical setting to reliably and
accurately predict PSA dynamics for individual patients. Allowing parameters to vary as treatment
progresses and studying the changes in key parameter values such as proliferation and death rates as
functions of time might be useful to describe and predict resistance mechanisms as suggested in the
work of Morken et al. [32].
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Figure 6. Simulations of fittings of androgen levels for Models 1 and 2. These two models have
comparable goodness in fitting androgen data as their derivations are very similar.
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Figure 7. Cancer cells in resistant and non-resistant patient for Model 1. For the non-resistant patient
we see a slight increase in volume over the course of several cycles. In the resistant patient we see that
cancer volume has grown substantially.
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Figure 8. Cancer cells in resistant and non-resistant patients for Model 2. For the non-resistant patient,
we see an increase in the volume of CR cells, but the original volume is about the same. In the
resistant patient, we see that cancer volume has grown to double the volume compared to the non
resistant patient.
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